Citi maintains Kenvue at 'buy' with a price target of $26.00
An analyst from Citi maintained Kenvue (NYSE: KVUE) at 'buy' with a price target of $26.00. Prior to this rating, Kenvue had 5 buy ratings, 6 hold ratings, and 0 sell ratings. For...
Neutral
or
Kenvue News & Analysis
-
-
Johnson & Johnson is getting rid of its script logo after more than 130 years
Health care giant Johnson & Johnson is unveiling a new logo to reflect its focus on pharmaceuticals and medical devices. The new logo will replace the script used since 1887 and will feature...
-
Tuesday’s Top Wall Street Analyst Upgrades and Downgrades: Amazon, DoorDash, Enbridge, Foot Locker, Kenvue, RTX, Tesla and More
Tuesday's top analyst upgrades and downgrades included Amazon.com, DoorDash, Enbridge, Foot Locker, Kenvue, Nu, RTX, SharkNinja and Tesla.
-
Wall Street analysts believe Kenvue sell-off is overdone
Kenvue (NYSE:KVUE) has received some positive commentary from analysts on Monday, with Deutsche Bank upgrading the stock and BofA telling investors it sees an attractive buy opportunity in...
-
Tesla, Apple, Hostess Brands, Boeing rise premarket; Alibaba falls
Investing.com -- U.S. futures traded slightly higher Monday, ahead of the release this week of fresh inflation data which could give guidance of future Federal Reserve monetary action. Here...
-
BofA Securities maintains Kenvue at 'buy' with a price target of $30.00
An analyst from BofA Securities maintained Kenvue (NYSE: KVUE) at 'buy' with a price target of $30.00. Prior to this rating, Kenvue had 4 buy ratings, 7 hold ratings, and 0 sell...
-
Canaccord Genuity Starts Kenvue Inc at Buy, 'great risk/reward opportunity here'
(Updated - September 7, 2023 7:24 AM EDT) Canaccord Genuity analyst initiates coverage on Kenvue Inc (KVUE) with a Buy rating and a price target of $28.00.The analyst comments "We are...
-
Argus Starts Kenvue Inc at Hold, 'valuations are reasonable'
(Updated - September 6, 2023 11:39 AM EDT) Argus initiates coverage on Kenvue Inc (KVUE) with a Hold rating.The analyst comments "We are launching coverage of Kenvue Inc. (KVUE) with a HOLD...
-
Johnson & Johnson's Growth Strategy Post Tylenol Parent Kenvue Split: Paving the Way for Medical Innovation
Johnson & Johnson (NYSE: JNJ) is gearing up to use the proceeds from the recent separation of its consumer-health segment Kenvue Inc (NYSE: KVUE) to bolster its growth in pharmaceuticals and...
-
HP, Peloton, Rite Aid fall premarket; Nvidia gains
Investing.com -- U.S. futures traded with small losses Wednesday, handing back some of the recent gains ahead of the release of more important labor market economic data. Here are some of...
-
Johnson & Johnson updates its FY guidance following Kenvue separation
Johnson & Johnson (NYSE:JNJ) has made updates to its financials and 2023 guidance after the completion of the Kenvue (NYSE:KVUE) separation. “The completion of this transaction uniquely...
-
Midday movers: Nvidia, Microsoft, Dollar Tree and more
Investing.com -- U.S. stocks were falling as Federal Reserve officials meet in Jackson Hole, Wyo., for their annual conference, with investors hoping for clues about the central bank's next...
-
Kenvue has a 'compelling relative valuation with approaching catalyst' - Goldman Sachs
Kenvue (NYSE:KVUE) was raised to Buy from Neutral at Goldman Sachs on Thursday, with analysts maintaining a $29 price target on the stock. They told investors that a valuation window has...
-
Nvidia, Microsoft, Alphabet, Splunk rise premarket; Boeing, Dollar Tree fall
Investing.com -- U.S. futures traded in a mixed fashion Thursday, with the tech sector dominating after Nvidia’s strong quarterly numbers. Here are some of the biggest premarket U.S....
-
Goldman Sachs upgrades Kenvue to 'buy' with a price target of $29.00
An analyst from Goldman Sachs upgraded Kenvue (NYSE: KVUE) from 'neutral' to 'buy' with a price target of $29.00. Prior to this rating, Kenvue had 3 buy ratings, 7 hold ratings, and 0 sell...
-
Kenvue Reports Full Separation from Johnson & Johnson
Kenvue Inc. (KVUE) (“Kenvue”) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company.“This is a historic moment for Kenvue and with a...
-
Johnson & Johnson Finalizes Separation of Kenvue , Announces Final Results of Exchange Offer
Johnson & Johnson (NYSE:JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of...
-
Kenvue to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
Kenvue Inc. (KVUE) will replace Advance Auto Parts Inc. (NYSE:AAP) in the S&P 500, and Advance Auto Parts will replace Emergent BioSolutions Inc. (EBS) in the S&P SmallCap 600 effective...
-
After-hours movers: Fabrinet, Zoom gain following earnings results
After-Hours Stock Movers: Tingo Group Inc (NASDAQ:TIO) 31% LOWER; announced today that it has further postponed its second-quarter 2023 earnings release and conference call and the filing of...
-
Advance Auto Parts Dropped from the S&P 500
Advance Auto Parts (AAP) is being removed from the S&P 500 index, to be replaced by Kenvue (KVUE), as announced by the S&P Dow Jones Indices.
-
Kenvue To Replace Advance Auto Parts In S&P 500 - Bloomberg
Kenvue To Replace Advance Auto Parts (NYSE:AAP) In S&P 500 -...
-
: J&J says Kenvue tender offer was oversubscribed, expects 23.8% of tendered shares will be exchanged
Johnson & Johnson JNJ said Monday that 802.7 million shares of its common stock were validly tendered and not validly withdrawn in a Kenvue Inc. KVUE tender offer that expired at midnight...
-
Citi maintains Kenvue at 'neutral' with a price target of $26.00
An analyst from Citi maintained Kenvue (NYSE: KVUE) at 'neutral' with a price target of $26.00. Prior to this rating, Kenvue had 2 buy ratings, 7 hold ratings, and 0 sell ratings. For...
-
Johnson & Johnson spinoff Kenvue to join S&P 500 index
Johnson & Johnson spinoff Kenvue to join S&P 500 index
-
After-hours movers: AppLovin surges on strong results, Disney gains on streaming price hikes
After-Hours Stock Movers: AppLovin (NASDAQ:APP) 21% HIGHER; {{erl-1172509||reported Q2 EPS of $0.22, $0.14 better than the analyst estimate of $0.08. Revenue for the quarter came in at $750...
-
: Kenvue, the J&J spinoff, will join the S&P 500 index
Kenvue Inc., maker of Tylenol, Benadryl and other household names in health-care products, is joining the S&P 500 index, index provider S&P Dow Jones Indices said late Wednesday.
-
Edward Jones initiates coverage of Kenvue at 'buy'
An analyst from Edward Jones initiated coverage of Kenvue (NYSE: KVUE) at 'buy' . Prior to this rating, Kenvue had 3 buy ratings, 7 hold ratings, and 0 sell ratings. For consensus...
-
Midday movers: Mattel, AMC Entertainment, Spotify and more
Investing.com -- U.S. stocks were rising on Monday as investors soaked in more corporate earnings ahead of this week's Federal Reserve meeting. Here are some of the biggest U.S. stock movers...
-
Wells Fargo says Johnson & Johnson's Kenvue spin may complete in Q3
On Monday, Johnson & Johnson (NYSE:JNJ) announced an exchange offer for its stockholders to choose shares of Kenvue (NYSE:KVUE), its newly listed consumer health unit. The company said it...
-
Mattel, AMC Entertainment, Chevron rise premarket; Tesla, Domino's fall
Investing.com -- U.S. futures traded higher Monday, starting a crucial week, which includes more corporate earnings and a Federal Reserve meeting, on a positive note. Here are some of the...
-
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue
Johnson & Johnson (NYSE:JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (KVUE) (“Kenvue”) through an exchange offer. Kenvue, formerly Johnson &...
-
UBS maintains Kenvue at 'sell' with a price target of $26.00
An analyst from UBS maintained Kenvue (NYSE: KVUE) at 'sell' with a price target of $26.00 from a prior price target of %currency%%price%. Prior to this rating, Kenvue had 2 buy ratings, 7...
-
Kenvue's first results are solid, dividend initiated
Kenvue (NYSE:KVUE) shares traded modestly higher in pre-market Thursday after the healthcare business delivered its first quarterly earnings report as an independent company. Kenvue...
-
Kenvue Declares $0.20 Quarterly Dividend; 3.2% Yield
Kenvue (KVUE) declared a quarterly dividend of $0.20 per share, or $0.8 annualized.The dividend will be payable on September 7, 2023, to stockholders of record on August 28, 2023, with an...
-
Cava Group surges in stock market debut amid hopes for IPO thaw
Investing.com -- Cava Group, the Mediterranean-style restaurant chain, popped in its trading debut on Thursday, doubling from its IPO price. Shares opened for trading at $42 each, up from...
-
Cava Group raises price range as IPO gears up
Investing.com -- Cava Group is gearing up for its initial public offering later this week, raising its price range on Monday. The Mediterranean-style restaurant chain disclosed in a...
-
Analysts mostly cautious on Kenvue given JNJ's intentions to sell more shares
Wall Street analysts launched research coverage on Kenvue (NYSE:KVUE) after the company made its trading debut earlier this month. Kenvue sold 172.8 million shares in the initial public...
-
Kenvue Announces Closing of IPO
Kenvue Inc. (KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
